cms.bioaccessla.com

Blog

  • Navigate Medical Device Clinical Trials in Chile: A Step-by-Step Guide

    Navigate Medical Device Clinical Trials in Chile: A Step-by-Step Guide

    Introduction

    While Chile offers a promising landscape for medical device clinical trials, the path to success is fraught with challenges that sponsors must navigate carefully.

    With a regulatory framework that encourages swift approvals and a robust healthcare system, Chile stands out as a strategic hub for early-stage clinical trials.

    However, navigating these complexities can often feel overwhelming for sponsors. Without a clear strategy, sponsors risk delays and setbacks in their trials.

    This guide will help you master the clinical trial process in Chile, giving you the insights you need to thrive in this competitive environment.

    Understand the Regulatory Landscape for Medical Device Trials in Chile

    Understanding the regulatory landscape for the medical device clinical trial Chile is crucial for successful study execution. Navigating the medical device clinical trial Chile necessitates a comprehensive grasp of the regulatory framework, primarily overseen by the Instituto de Salud Pública (ISP). Here are the essential steps to ensure compliance:

    1. Familiarize Yourself with Relevant Laws: Review the Medical Devices Law and associated regulations, particularly Law N° 20.120, which outlines the requirements for human research.
    2. Obtain Ethical Approval: Have you secured endorsement from an accredited Ethics Committee (EC) before commencing any study? While this process is voluntary, it is critical for ensuring compliance with ethical standards.
    3. Prepare Required Documentation: Compile all necessary documentation, including the clinical research protocol, informed consent forms, and any prior approvals. Ensure that all documents adhere to ISP standards to facilitate a smooth review process for the medical device clinical trial in Chile.
    4. Understand approval timelines for medical device clinical trial Chile: Typically, securing authorization for medical device studies in Chile takes around 30 days, but this can vary based on study complexity and the completeness of the submitted documentation.
    5. Engage with Local Experts: Have you considered collaborating with local compliance consultants or specialized CROs like bioaccess®? Their expertise can help you navigate the approval landscape and expedite the authorization process.

    By adhering to these steps, sponsors can utilize Chile’s advantageous regulatory landscape, marked by efficient approval procedures and a strong healthcare system, to expedite their research studies. Embracing these steps not only streamlines your research process but also positions you for success in a competitive market.

    Each box represents a crucial step in the process of conducting medical device trials in Chile. Follow the arrows to see how each step leads to the next, ensuring you meet all regulatory requirements.

    Prepare for Your Trial: Site Selection and Patient Recruitment Strategies

    Strategic site selection and effective patient recruitment are critical for the success of your medical device clinical trial in Chile. Follow these steps:

    1. Identify Suitable Sites: Assess potential clinical research locations based on their experience with medical device studies, patient demographics, and infrastructure. Leverage bioaccess®’s network of over 50 pre-qualified sites to streamline this process. This ensures compliance with ICH-GCP standards and local regulations from authorities like the Instituto de Salud Pública (ISP) and the Agencia Nacional de Medicamentos (ANAMED).
    2. Conduct Feasibility Studies: Assess the availability of eligible patients and the site’s capacity to meet enrollment goals. This can involve reviewing historical data on patient recruitment and retention, which is crucial for understanding site performance and optimizing recruitment strategies. You’ll find that Bioaccess® offers valuable insights into market access strategies that can really help inform your feasibility studies.
    3. Develop a Recruitment Plan: Create a comprehensive recruitment strategy that includes digital marketing, community outreach, and partnerships with local healthcare providers. Customize your messaging to connect with the intended patient group, highlighting the advantages of involvement in the medical device clinical trial Chile. How can you engage with local communities to enhance trust and participation rates?
    4. Utilize Technology: Leverage digital platforms and social media to reach potential participants effectively. Consider using telemedicine for initial consultations to broaden your reach and facilitate engagement with patients who may have logistical barriers to in-person visits. Recent studies indicate that digital recruitment strategies can significantly enhance patient enrollment by targeting specific demographics, a strategy supported by bioaccess®’s insights.
    5. Engage Patient Advocacy Groups: Collaborate with patient advocacy organizations to enhance recruitment efforts and build trust within the community. These groups can provide valuable insights into patient needs and preferences, helping to refine your recruitment messaging and strategies. Bioaccess® encourages partnerships with these organizations to further strengthen recruitment efforts.

    By prioritizing these tailored strategies, you can significantly enhance your chances of successful patient recruitment in Chile.

    Each box represents a crucial step in preparing for your clinical trial. Follow the arrows to see how each step leads to the next, helping you understand the entire process of site selection and patient recruitment.

    Execute the Trial: Operational Processes and Compliance Monitoring

    Executing a medical device clinical trial in Chile involves unique operational challenges that require meticulous attention to compliance. Here are several key processes to consider:

    1. Commence the Study: After obtaining all essential approvals from oversight bodies such as ANVISA and COFEPRIS, kick off the study with a meeting that includes all stakeholders, such as site personnel and researchers. This meeting is crucial for aligning expectations and clarifying roles.
    2. Implement Training Programs: Ensure that all site personnel are thoroughly trained on the study protocol, ICH-GCP guidelines, and specific regulatory requirements. When training programs are effective, they not only boost compliance but also significantly lower the chances of deviations. Tailor training to the study specifics, utilizing interactive modules to engage staff effectively.
    3. Monitor Compliance: Establish a robust compliance oversight plan that includes regular site visits, information verification, and audits. In 2026, following ICH-GCP standards is essential, as statistics show that non-compliance can cause significant delays in trial approval and inflate costs. Regular audits help identify potential compliance gaps early, allowing for timely corrective actions.
    4. Collect Information: Utilize electronic information capture (EIC) systems to streamline collection and management. These systems enable real-time information entry, improving precision and reducing mistakes. The transition to EDC has been nearly universal in clinical research, providing immediate data availability for review and reducing the time required for data processing.
    5. Address Compliance Issues: Proactively identify and resolve any compliance concerns that arise during the study. This may involve implementing corrective actions, providing additional training, or making necessary protocol amendments. Ongoing oversight and effective communication with site personnel are crucial to uphold compliance and guarantee participant safety throughout the study.

    By adhering to these guidelines, research teams can effectively navigate the complexities of medical device clinical trial Chile. By prioritizing compliance, research teams not only enhance trial integrity but also pave the way for successful outcomes in the competitive Medtech landscape.

    Each box represents a crucial step in the clinical trial process. Follow the arrows to see how each step leads to the next, ensuring that all necessary actions are taken to maintain compliance and operational integrity.

    Manage Data and Submit for Regulatory Approval After the Trial

    Completing a clinical trial is just the beginning; the path to regulatory approval is where the real challenges lie. After finishing the trial, effective data management and regulatory submission preparation are critical steps:

    1. Information Management: Accurately compile and analyze all trial results. Use statistical software to perform essential analyses and create detailed reports that meet compliance standards.
    2. Prepare Regulatory Submission: Assemble all necessary documentation for regulatory submission, including clinical study reports, safety information, and efficacy results. Make sure your submission meets the Instituto de Salud Pública (ISP) requirements, which usually means following ICH-GCP standards.
    3. Engage with Regulatory Authorities: Maintain proactive communication with the ISP throughout the submission process. This engagement can facilitate the resolution of any questions or concerns that may arise, ensuring a smoother review process.
    4. Submit for Approval: Submit the compiled documentation to the ISP for review. Typically, you can expect an approval timeline of around 30 business days, but keep in mind that this can change depending on how complex your submission is and how complete your data looks.
    5. Follow Up: After submission, actively follow up with the ISP to monitor the status of your application. Be prepared to address any additional requests for information promptly, which can help expedite the approval process. Your diligence in managing data and engaging with authorities can make all the difference in achieving a successful outcome.

    This flowchart shows the steps you need to take after completing a clinical trial to get regulatory approval. Start at the top and follow the arrows down to see how each step leads to the next, from managing your data to following up after submission.

    Conclusion

    The medical device clinical trial landscape in Chile presents both challenges and unparalleled opportunities for sponsors seeking to accelerate their research. Understanding the essential steps – from regulatory compliance to patient recruitment – empowers stakeholders to position their studies for success in a competitive environment.

    Key insights include:

    • The necessity of familiarizing oneself with the regulatory landscape governed by the Instituto de Salud Pública (ISP)
    • Securing ethical approvals
    • Engaging with local experts to streamline the approval process
    • Strategic site selection
    • Innovative patient recruitment strategies

    These are critical for achieving enrollment goals, while robust compliance monitoring ensures trial integrity throughout execution.

    In conclusion, by not seizing these strategic advantages, sponsors risk falling behind in the rapidly evolving MedTech landscape. Leveraging Chile’s efficient regulatory pathways, cost-effectiveness, and patient access can significantly accelerate the journey from concept to market, ultimately contributing to advancements in the MedTech field.

    Frequently Asked Questions

    What is the primary regulatory authority overseeing medical device clinical trials in Chile?

    The primary regulatory authority overseeing medical device clinical trials in Chile is the Instituto de Salud Pública (ISP).

    What key law should be reviewed when planning a medical device trial in Chile?

    It is essential to review the Medical Devices Law and associated regulations, particularly Law N° 20.120, which outlines the requirements for human research.

    Is ethical approval mandatory for medical device clinical trials in Chile?

    While obtaining ethical approval from an accredited Ethics Committee (EC) is voluntary, it is critical for ensuring compliance with ethical standards before commencing any study.

    What documentation is required for a medical device clinical trial in Chile?

    Required documentation includes the clinical research protocol, informed consent forms, and any prior approvals, all of which must adhere to ISP standards for a smooth review process.

    What is the typical timeline for securing authorization for medical device studies in Chile?

    The typical timeline for securing authorization for medical device studies in Chile is around 30 days, although this may vary based on the study’s complexity and the completeness of the submitted documentation.

    How can local experts assist in the medical device trial process in Chile?

    Collaborating with local compliance consultants or specialized Contract Research Organizations (CROs) like bioaccess® can help navigate the approval landscape and expedite the authorization process.

    What advantages does Chile offer for conducting early-stage clinical trials?

    Chile offers an advantageous regulatory landscape characterized by efficient approval procedures and a strong healthcare system, which can expedite research studies and enhance competitiveness in the market.

    List of Sources

    1. Understand the Regulatory Landscape for Medical Device Trials in Chile
      • Master The Clinical Trial Approval Process In … | bioaccess® (https://bioaccessla.com/blog/master-the-clinical-trial-approval-process-in-chile)
      • Chile (ISP – Instituto de Salud Pública) – PharmaRegulatory.in – India’s Regulatory Knowledge Hub (https://pharmaregulatory.in/country-specific-regulatory-affairs/chile-isp-instituto-de-salud-publica)
      • Master Regulatory Compliance for Trials in Chi… | bioaccess® (https://bioaccessla.com/blog/master-regulatory-compliance-for-trials-in-chile-effectively)
      • Latin America the ‘Hidden Gem’ for First-in-Human Medical Device Trials (https://clinicalresearchnewsonline.com/news/2025/08/14/latin-america-the-hidden-gem-for-first-in-human-medical-device-trials)
    2. Prepare for Your Trial: Site Selection and Patient Recruitment Strategies
      • Evolving Trends in Latin American Participation in Global Oncology Clinical Trials: A Decade of Phase III Activity (2013-2022) | JCO Global Oncology (https://ascopubs.org/doi/10.1200/GO-25-00411)
      • Clinical Trial Site Selection: Key Challenges & Solutions for Phase 3 Success (https://precisionformedicine.com/blog/clinical-trial-site-selection-key-challenges-solutions-for-phase-3-success)
      • Patient Recruitment and Retention Considerations for Clinical Trials in Latin America (https://clinicaltrialsarena.com/comment/patient-recruitment-retention-considerations)
      • Enhancing site selection strategies in clinical trial recruitment using real-world data modeling – PMC (https://pmc.ncbi.nlm.nih.gov/articles/PMC10927105)
      • Clinical studies: the challenge of patient recruitment (https://servier.com/en/newsroom/clinical-studies-patient-recruitment)
    3. Execute the Trial: Operational Processes and Compliance Monitoring
      • Medical Device Clinical Trials: An Overview [+Types] (https://greenlight.guru/blog/medical-device-clinical-trials)
      • Complete Guide to EDC Systems in Clinical Trials (2026) (https://triticon.com/blogs/usa/complete-guide-edc-systems-2026)
      • Importance of Compliance in Clinical Trials (https://primerevivalresearch.com/blogs/importance-of-compliance-in-clinical-trials)
      • Site Training for Clinical Trial success | ICON plc (https://iconplc.com/insights/blog/2024/03/25/site-training-clinical-trial-success)
      • FDA Guidance on Statistical Methods for Clinical Trials – ECA Academy (https://gmp-compliance.org/gmp-news/fda-guidance-on-statistical-methods-for-clinical-trials)
    4. Manage Data and Submit for Regulatory Approval After the Trial
      • Master Regulatory Compliance for Trials in Chi… | bioaccess® (https://bioaccessla.com/blog/master-regulatory-compliance-for-trials-in-chile-effectively)
      • 2026 Clinical Data Trend Report | Veeva (https://veeva.com/2026-clinical-data-trend-report)
      • Clinical Data Management: stakes & regulations (https://efor-group.com/en/clinical-data-management-art-of-managing-clinical-trial-data)
      • FDA Guidance on Statistical Methods for Clinical Trials – ECA Academy (https://gmp-compliance.org/gmp-news/fda-guidance-on-statistical-methods-for-clinical-trials)
      • 19 Inspirational Quotes About Data | The Pipeline | ZoomInfo (https://pipeline.zoominfo.com/operations/19-inspirational-quotes-about-data)

  • Master Early Feasibility Study in Chile: Steps for Success

    Master Early Feasibility Study in Chile: Steps for Success

    Introduction

    Early feasibility studies (EFS) in Chile offer a promising yet challenging landscape for MedTech and biopharma companies. With expedited regulatory approval timelines and a diverse patient demographic, Chile stands out as a strategic hub for conducting EFS. This environment enables startups to gather crucial safety and efficacy data swiftly. However, navigating these complexities can be daunting for many companies. The local regulatory framework and potential approval delays raise pressing questions:

    1. What steps can you take to master early feasibility studies in Chile?
    2. How can you unlock the region’s potential for clinical innovation?

    Exploring these essential strategies reveals the path to success in this competitive arena.

    Understand Early Feasibility Studies and Their Importance in Chile

    In the fast-evolving landscape of clinical research, an early feasibility study in Chile is essential for assessing the viability of new medical devices or treatments. How can the effective governance framework and diverse patient demographics in this South American nation enhance the benefits of EFS? These studies allow companies to gather vital information on safety and efficacy, greatly enhancing the likelihood of successful regulatory submissions.

    The early feasibility study Chile holds strategic significance in the region, especially because of the swift access to clinical data. This is crucial for startups aiming to attract investors and secure funding. Regulatory approval timelines in this region can be as short as 30-90 days, enabling companies to achieve their first-in-human milestones more swiftly than in traditional markets. This competitive advantage positions Chile as an ideal site for an early feasibility study in MedTech, especially for startups navigating the complexities of compliance pathways effectively.

    The Chilean legislative framework, unchanged since 2006, poses unique challenges. However, these can be mitigated through careful planning and collaboration with local experts. By utilizing the expertise of specialized contract research organizations like bioaccess®, startups can ensure adherence to ICH-GCP standards and facilitate smoother interactions with oversight authorities such as ANVISA. This method not only improves the reliability of the clinical data produced but also conforms to the FDA’s acceptance standards for international clinical trial data, further reinforcing the region’s status as a favorable destination for early feasibility study Chile. By leveraging local expertise, startups can not only navigate regulatory challenges but also enhance their chances of success in the competitive MedTech arena.

    This mindmap illustrates the key components of early feasibility studies in Chile. Start at the center with the main topic, then explore the branches to see how different factors like regulatory timelines and local expertise contribute to the success of these studies.

    Navigating the compliance framework is crucial for conducting clinical research in Chile, where regulatory oversight is stringent and complex. To effectively carry out an initial feasibility assessment in the region, understanding the compliance framework is essential. The Instituto de Salud Pública (ISP) is the main oversight body supervising clinical trials in the country. Here are the essential steps to ensure compliance:

    1. Understand the Regulatory Framework: Familiarize yourself with Decree 3/2010, which details the requirements for medical device registration and clinical trials in Chile. Compliance with ICH-GCP standards is mandatory. Understanding the complexity of the certification and approval process is vital for success. Staying updated on regulatory changes from bioaccess® can provide essential insights into any modifications that may influence your research.
    2. Obtain Ethics Committee Approval: Before commencing your research, submit your research protocol to an Institutional Review Board (IRB) for ethical evaluation. This step is vital for ensuring participant safety and adherence to ethical standards, which is a key focus for bioaccess® in facilitating first-in-human trials. Notably, ethics approvals in Chile can be accelerated, allowing for quicker project initiation compared to other regions.
    3. Submit Regulatory Applications: Prepare and send your application to the ISP, including all necessary documentation such as study protocols, informed consent forms, and safety information. Align your submission with the ISP’s guidelines to prevent delays, as the average approval duration can exceed six months. Working with bioaccess® can simplify this process. Their expertise in compliance can help ensure your data meets FDA and EMA standards.
    4. Engage with Local Experts: Collaborating with local CROs or compliance consultants can provide valuable insights into the intricacies of the Chilean approval environment, facilitating a smoother approval process. Utilizing the strategic benefits of executing clinical trials in Latin America, such as quicker activation and cost-effectiveness, can greatly enhance your research. Bioaccess® offers tailored support to help MedTech startups navigate these complexities effectively.

    By following these steps, sponsors can navigate the complexities of the Chilean regulatory framework. This ensures timely and compliant execution of early feasibility study Chile assessments. Embracing these steps not only ensures compliance but also positions your research for success in a competitive landscape.

    Each box represents a crucial step in the process of conducting clinical research in Chile. Follow the arrows to see the order in which these steps should be completed to ensure compliance and success.

    Plan and Execute Your Early Feasibility Study: Key Steps and Strategies

    Successfully planning and executing an early feasibility study in Chile requires a strategic approach to overcome regulatory challenges and ensure participant safety. Here are several key steps to consider:

    1. Define Objectives and Scope: Clearly outline the objectives of your research, including specific questions regarding the device’s safety and efficacy. This clarity will guide how you design your research and develop your protocol.
    2. Conduct a Literature Review: Collect existing research and information related to your device and comparable examinations. Identifying gaps in knowledge will inform your research design and enhance its relevance.
    3. Develop a Research Protocol: Create a detailed research protocol that includes methodology, participant criteria, and data collection methods. Ensure that your protocol aligns with regulatory requirements, including compliance with ICH-GCP standards and FDA acceptance criteria.
    4. Obtain Regulatory Approval: Submit your research protocol to the Instituto de Salud Pública (ISP) for approval. This step is crucial for ensuring compliance and protecting participant safety. The CEC review and approval typically takes 4-8 weeks, depending on device complexity.
    5. Recruit Participants: Develop a robust recruitment strategy targeting the appropriate patient population. Engage with local healthcare providers and leverage community networks to enhance recruitment efforts. Notably, Chile’s patient referral networks are physician-driven, allowing for faster recruitment through established relationships.
    6. Monitor and Collect Information: Implement a rigorous monitoring plan to ensure information integrity and participant safety throughout the study. Consistently review information and make modifications as needed to address any emerging issues. Ensure that 100% of critical information points undergo source verification documentation to maintain compliance and quality.

    Navigating the complex regulatory landscape can be daunting for sponsors. However, by following these steps, sponsors not only streamline their processes but also enhance their chances of successful market entry. This methodical approach not only mitigates risks but also positions sponsors for a competitive edge in the clinical research landscape.

    Each box represents a crucial step in planning and executing your feasibility study. Follow the arrows to see how each step leads to the next, ensuring a smooth and compliant research process.

    Overcome Challenges in Conducting Early Feasibility Studies in Chile

    Conducting early feasibility study Chile can be fraught with challenges that require strategic navigation to ensure success. Here are some key hurdles and how to effectively manage them:

    1. Approval Delays: Navigating the approval landscape in Chile can be a daunting task, often leading to frustrating delays that hinder progress. Collaborating with local compliance experts is essential. They can provide guidance and improve communication with the Instituto de Salud Pública (ISP). Proactive engagement with the ISP can streamline the approval process, which typically lasts about 30 business days.
    2. Patient Recruitment Issues: Recruiting participants, particularly from niche populations, can be a significant hurdle. Without a targeted recruitment strategy, you risk falling short on participant numbers, which could jeopardize the success of your study. Developing a targeted recruitment strategy is crucial. This includes outreach to local healthcare providers and community organizations, enhancing visibility and fostering trust within the community. Utilizing online platforms for advertising can also improve recruitment outcomes.
    3. Cultural Considerations: Grasping the cultural nuances can make a real difference in how you engage and retain participants. Customizing communication and recruitment tactics to connect with the local community ensures that potential participants feel at ease and well-informed about the research. Engaging with local patient advocacy groups can further enhance recruitment efforts.
    4. Information Management Challenges: Preserving information integrity and adherence to regulatory standards can be overwhelming. Implementing robust data management systems and conducting regular monitoring are essential to ensure high-quality data throughout the research. Compliance with ICH-GCP standards is mandatory, and meticulous documentation is required for all submissions to the ISP.
    5. Resource Limitations: Startups often face constraints in funding and personnel. Collaborating with local CROs or research institutions can offer additional resources and expertise to aid your project. Partnering with established organizations like bioaccess® can facilitate access to a network of pre-qualified clinical trial sites and experienced personnel, enhancing the overall efficiency of the study.

    By addressing these challenges head-on, you can position your study for success and contribute valuable insights to the clinical research landscape in Chile.

    Each box represents a challenge faced during feasibility studies, and the arrows lead to strategies for overcoming those challenges. Follow the flow to see how to navigate each hurdle effectively.

    Conclusion

    The potential for MedTech and biopharma companies in Chile is vast, yet navigating the complexities of clinical trials requires strategic foresight. By leveraging the unique regulatory environment, organizations can maximize their chances of success. Swift approval timelines and diverse patient demographics further enhance this opportunity, making Chile a strategic location for early feasibility studies.

    Throughout this article, we outlined essential steps for conducting successful early feasibility studies. Understanding the regulatory framework, obtaining necessary approvals, and developing effective recruitment strategies are key. Collaborating with local experts and contract research organizations like bioaccess® is crucial for streamlining processes and mitigating potential challenges. By focusing on compliance with ICH-GCP standards and engaging with local healthcare providers, sponsors can enhance their study’s reliability and efficiency.

    In conclusion, the potential for success in the Chilean clinical trial landscape is immense. Startups and established companies alike must embrace the outlined best practices. As the demand for innovative medical solutions continues to grow, the strategic advantages offered by early feasibility studies in Chile present an invaluable opportunity. It’s crucial for companies to take action, tap into local expertise, and prioritize compliance. This approach ensures their research meets regulatory requirements and adds valuable insights to the global MedTech ecosystem.

    Frequently Asked Questions

    What is the purpose of an early feasibility study (EFS) in Chile?

    An early feasibility study in Chile assesses the viability of new medical devices or treatments, allowing companies to gather vital information on safety and efficacy, which enhances their chances of successful regulatory submissions.

    Why is Chile considered a strategic location for early feasibility studies?

    Chile is strategic for early feasibility studies due to its swift access to clinical data, with regulatory approval timelines as short as 30-90 days. This enables companies to achieve first-in-human milestones more quickly than in traditional markets.

    How can startups benefit from the governance framework in Chile?

    The effective governance framework and diverse patient demographics in Chile enhance the benefits of early feasibility studies by providing a competitive advantage, particularly for startups looking to attract investors and secure funding.

    What challenges do startups face in Chile’s regulatory environment?

    Startups may encounter challenges due to the Chilean legislative framework, which has remained unchanged since 2006. However, these challenges can be mitigated through careful planning and collaboration with local experts.

    How can specialized contract research organizations assist startups in Chile?

    Specialized contract research organizations, like bioaccess®, can help startups ensure adherence to ICH-GCP standards, facilitate smoother interactions with regulatory authorities such as ANVISA, and improve the reliability of clinical data produced.

    What are the compliance requirements for conducting clinical trials in Chile?

    Compliance with ICH-GCP standards and alignment with FDA acceptance criteria for international clinical trial data are essential for conducting clinical trials in Chile.

    What role does local expertise play in the success of early feasibility studies?

    Leveraging local expertise allows startups to navigate regulatory challenges effectively, enhancing their chances of success in the competitive MedTech arena in Chile.

    List of Sources

    1. Understand Early Feasibility Studies and Their Importance in Chile
      • Latin America’s Landscape For Medtech Clinical Trials (https://clinicalleader.com/doc/latin-america-s-landscape-for-medtech-clinical-trials-0001)
      • Early Feasibility Studies in Latin America (https://greenlight.guru/blog/early-feasibility-studies-in-latin-america)
    2. Navigate Regulatory Requirements for Early Feasibility Studies in Chile
      • Case Studies – QPS Custom-Built Research (https://qps.com/resources/case-studies)
      • Master Regulatory Compliance for Trials in Chi… | bioaccess® (https://bioaccessla.com/blog/master-regulatory-compliance-for-trials-in-chile-effectively)
    3. Plan and Execute Your Early Feasibility Study: Key Steps and Strategies
      • First-in-Human Medical Device Trial in Chile | bioaccess® (https://bioaccessla.com/blog/first-in-human-medical-device-trial-chile)
      • Master Regulatory Compliance for Trials in Chi… | bioaccess® (https://bioaccessla.com/blog/master-regulatory-compliance-for-trials-in-chile-effectively)
      • Early Feasibility Studies in Latin America (https://greenlight.guru/blog/early-feasibility-studies-in-latin-america)
    4. Overcome Challenges in Conducting Early Feasibility Studies in Chile
      • Master Regulatory Compliance for Trials in Chi… | bioaccess® (https://bioaccessla.com/blog/master-regulatory-compliance-for-trials-in-chile-effectively)
      • Early Feasibility Studies: Top 6 Considerations | MED Institute (https://medinstitute.com/blog/early-feasibility-studies-top-6-considerations)
      • Master The Clinical Trial Approval Process In … | bioaccess® (https://bioaccessla.com/blog/master-the-clinical-trial-approval-process-in-chile)
      • Keys to Maximize Patient Recruitment (https://linical.com/articles-research/keys-to-maximize-patient-recruitment)

  • Hello world!

    Welcome to WordPress. This is your first post. Edit or delete it, then start writing!

  • Fda’s December 2025 RWE Guidance And Latin American Clinical Data: A New Strategic Window For Medical Device Sponsors

    FDA’s December 2025 RWE Guidance and Latin American Clinical Data: A New Strategic Window for Medical Device Sponsors

    In December 2025, the FDA finalized an update to its 2017 guidance on the use of real-world evidence (RWE) in medical device regulatory submissions. The revision is narrow on paper but strategically significant: the FDA no longer always requires sponsors to submit or secure access to identifiable individual participant-level data when using real-world data sources to support an IDE, 510(k), De Novo, PMA, or HDE submission. Aggregate, de-identified, and privacy-restricted data sources are now acceptable with appropriate justification.

    For MedTech sponsors running first-in-human and early-feasibility clinical trials in Latin America, this shift creates a new strategic window — one worth understanding before your next regulatory conversation with the FDA.

    What Changed in the December 2025 Guidance

    The 2017 guidance effectively expected sponsors to obtain patient-level records when using real-world data sources — a high bar when the underlying data came from registries, hospital systems, or health databases outside the US that operated under privacy rules limiting sponsor access. The December 2025 revision explicitly acknowledges that reality and redirects the evaluation toward a different question: whether the evidence is scientifically sound and fit for purpose, regardless of whether the sponsor can access every underlying record.

    Three practical shifts flow from this:

    • De-identified and aggregate datasets are now usable. Sponsors no longer need to demonstrate access to identifiable records when privacy rules forbid it, as long as data relevance, reliability, and traceability are documented.
    • International data sources are explicitly addressed. The FDA recognizes that privacy and legal frameworks outside the US (GDPR, Latin American data protection laws, regional privacy statutes) may limit participant-level sharing — and says so directly.
    • The burden shifts to transparency. Where participant-level data are unavailable, sponsors must clearly document what data are available, who has access, and how limitations affect the results.

    The guidance still applies only to medical devices. The parallel drug and biologics RWE guidance remains unchanged for now, with an FDA statement that updates are under consideration.

    Why This Matters for Latin American Clinical Data

    Latin America has spent the last decade becoming a practical venue for FIH and early-feasibility medical device trials. The region offers 40% faster regulatory approval timelines, 30% lower overall trial costs, and ethics-committee turnaround of 4 to 8 weeks against 6 to 12 months in the US and EU. Clinical data generated in the region are already accepted by the FDA under 21 CFR 812.28 when ICH-GCP compliance is documented.

    What the December 2025 guidance adds is a second, complementary path: real-world evidence sourced from Latin American healthcare systems, registries, and post-market data — data that was previously awkward to incorporate into US submissions because of cross-border privacy restrictions. Under the new guidance, a MedTech sponsor can now more credibly combine:

    • A prospective FIH or early-feasibility study conducted under ICH-GCP at accredited Latin American sites, producing the core safety and effectiveness data;
    • Supporting real-world evidence drawn from regional hospital registries, payer databases, and post-market surveillance — including aggregate-only sources — to strengthen external validity, capture long-term outcomes, or support indication expansion.

    Strategic Implications for MedTech Founders

    For founders and regulatory directors planning a device program, the December 2025 revision opens three concrete strategic options:

    • Smaller, faster pivotal studies. When aggregate RWE can support effectiveness or safety endpoints, prospective sample sizes can sometimes be reduced, shortening enrollment timelines and cost.
    • Stronger post-market commitments. FDA post-market surveillance obligations can increasingly be satisfied with regional registry data and claims-like datasets from Latin American health systems, rather than expensive prospective US post-approval studies.
    • Indication expansion without re-running a full trial. When a device is approved for one indication, RWE from real-world use in Latin American hospitals can support label expansion submissions with a much smaller prospective component.

    What You Need to Get Right

    The FDA is not lowering the scientific bar. The agency explicitly reinforced that relevance and reliability remain the core evaluation criteria. Practically, sponsors planning to use Latin American RWE in a submission should:

    • Prespecify the protocol. Define in writing how the RWE data source will be used, what endpoints it supports, and how missing data will be handled — before any analysis runs.
    • Document data provenance. Source systems, extraction dates, curation steps, and validation activities must be traceable. When patient-level access is not available, this documentation burden increases.
    • Address bias and confounding explicitly. Sensitivity analyses, transparent endpoint definitions, and prespecified analytic assumptions are essential.
    • Validate key data elements. Device exposure capture (through UDIs or alternative approaches), clinical outcomes, and covariates must be validated against a gold standard where feasible.

    Frequently Asked Questions

    Does the December 2025 FDA guidance apply to drug or biologic submissions?
    No. The current revision applies to medical device submissions only. The FDA has indicated that it intends to consider parallel updates for drugs and biologics, but those have not been finalized. Drug sponsors should continue to engage the FDA early on a case-by-case basis when proposing RWE approaches.

    Can I use a Latin American hospital registry as a real-world data source for an FDA device submission?
    Yes, provided the data are relevant to the population, exposure, and outcomes of interest, and reliable in terms of generation, curation, processing, and validation. The December 2025 guidance explicitly accepts aggregate and de-identified data sources when participant-level access is restricted by local privacy law, so long as sponsors transparently document those limitations.

    How does this guidance interact with 21 CFR 812.28 for prospective trials?
    The two frameworks are complementary. 21 CFR 812.28 governs acceptance of prospective clinical investigations conducted outside the US, requiring ICH-GCP compliance. The December 2025 RWE guidance governs acceptance of real-world data — registries, claims, electronic health records — that are not generated through a prospective clinical trial. A well-designed Latin American regulatory strategy can now use both pathways in a single submission.

    bioaccess® is a contract research organization purpose-built for first-in-human and early-feasibility medical device trials, operating across 10 Latin American countries with a 12-month timeline guarantee. Learn more at bioaccessla.com or book a strategy conversation at bioaccessla.com/book-a-meeting.

  • Ethics Committee Amendment Cycles In Latin America: How To Protect Your FIH Timeline

    Ethics Committee Amendment Cycles in Latin America: How to Protect Your FIH Timeline

    When first-in-human (FIH) medical device sponsors benchmark Latin America against the US and EU, they typically focus on initial regulatory approval times. That is the right place to start — ethics committee (EC) approvals in Colombia, Mexico, Brazil, and Chile routinely land in 4 to 8 weeks, compared with 6 to 12 months in the US and EU. But initial approval is only the first checkpoint. What most sponsors underestimate is how EC amendment cycles affect the total timeline once the trial is active.

    Across our operational portfolio, amendment handling is where many sponsors lose — or preserve — weeks of study duration. The patterns below come from years of managing EC submissions for FIH medical device studies across the region, anonymized and generalized for this post.

    Why Amendments Happen More Often Than Sponsors Expect

    FIH studies are inherently iterative. Early safety signals, minor device refinements, protocol clarifications, investigator rotations, and updated informed consent forms all generate amendments. For a typical 10-patient FIH study running 12 months, sponsors should plan for three to six protocol or document amendments during the life of the trial — sometimes more for device studies with embedded software or evolving clinical endpoints.

    In the US and EU, each of these amendments often triggers a fresh cycle through the IRB or ethics body, with turnaround times that can stretch from three weeks to several months depending on whether the committee considers the change substantial. Every week a protocol amendment sits in review is a week the site cannot enroll under the new version.

    The Amendment Turnaround Advantage in Latin America

    Operational data from FIH studies across the region shows a very different cadence. When a well-prepared amendment dossier is submitted to an experienced EC in Colombia, Mexico, or Brazil, approval typically returns in one to three weeks. In several recent studies, amendment approvals have come back in as little as 24 hours to seven days when the change is administrative (site address updates, CV refreshes, minor consent language edits).

    Three structural reasons explain the speed difference:

    • Higher EC meeting frequency. Many accredited Latin American ethics committees meet weekly or biweekly, compared with monthly cycles at many US academic IRBs.
    • Shorter queues. ECs at private hospitals and specialized research centers carry lighter portfolios than large US academic IRBs juggling hundreds of active protocols.
    • Tighter sponsor–EC communication. In many LATAM centers, the ethics coordinator and the site principal investigator share an institutional reporting line, making pre-submission clarification conversations possible in ways that rarely happen in the US.

    Where Sponsors Still Lose Time — Avoidable Mistakes

    The speed advantage is real, but it is not automatic. Three failure patterns consistently slow down amendments in the region:

    • Inconsistent document versioning across countries. In multi-country FIH studies, sponsors often submit slightly different amendment packages to different ECs, which generates clarification requests and restarts the clock.
    • Missing translation certifications. Several regulators and ECs in the region require certified Spanish or Portuguese translations of English-language source documents. Un-certified translations are a common cause of rejection on first pass.
    • Late-stage investigator brochure updates. Sponsors who revise the investigator brochure after starting enrollment often trigger mandatory re-consent of already-enrolled subjects. Planning brochure updates before first patient in — or batching them with other substantial amendments — preserves both timeline and data integrity.

    What Founders and Regulatory Directors Should Do

    A practical playbook for protecting your FIH timeline during the amendment phase:

    • Pre-build an amendment calendar. At study start-up, map out the likely amendments you will need in the first six months — IB updates, consent refinements, site additions — and pre-stage the documents.
    • Harmonize across countries from day one. Use identical protocol and consent templates across all participating countries, with only legally mandated local language and regulatory footers differing. This dramatically reduces EC back-and-forth.
    • Use a single regulatory project manager across the region. Consistent version control and a single point of submission accountability across Colombia, Mexico, Brazil, Argentina, and Chile eliminates the most common source of delay.
    • Budget for translation certification up front. Build certified translation costs into the study budget rather than scrambling during each amendment.

    For MedTech founders running a 12-month FIH program, disciplined amendment management is worth roughly two to four weeks of preserved timeline — enough to either move a milestone forward or absorb an unexpected delay elsewhere without slipping the study closeout date. In an industry where 90% of healthcare startups fail because they run out of capital before generating clinical data, those weeks are strategic runway.

    Frequently Asked Questions

    How long does a typical protocol amendment take in Latin America versus the US?
    For experienced ethics committees in Colombia, Mexico, Brazil, Argentina, and Chile, substantial amendments typically receive approval in one to three weeks. Minor administrative amendments can approve in seven days or less. By comparison, US academic IRBs often take four to eight weeks for substantial amendments and two to four weeks for minor ones.

    Do all amendments require re-consent of already-enrolled subjects?
    No. Only amendments that materially change the risk-benefit profile, introduce new procedures, or alter the primary informed consent elements require re-consent. Administrative changes, site additions, and CV updates do not. A well-designed amendment strategy bundles consent-relevant changes to minimize re-consent events.

    Can amendment delays invalidate FDA bridge data from a LATAM study?
    No, provided the study remains in compliance with ICH-GCP and 21 CFR 812.28 throughout. What matters for FDA acceptance is that each amendment is properly reviewed, documented, and approved by the responsible ethics committee before implementation — not how long the approval took.

    bioaccess® is the world’s only CRO built exclusively for first-in-human clinical trials. We execute FIH and early-feasibility studies across 10 Latin American countries with a 12-month timeline guarantee. Explore our approach at bioaccessla.com or estimate a study at bioaccessla.com/clinical-trial-calculator.